ArticleFrontiers in psychiatry2026
Cognitive function and depressive symptoms in major depressive disorder: a smartphone-based study of outpatients from a sleep-disorders clinic in China.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subjective cognitive dysfunction is common in patients with major depressive disorder (MDD), but its relationship with depressive symptoms and treatment response remains unclear, especially in routine clinical settings in China. Methods: We conducted an 8-week retrospective observational study using routinely collected data from the "Good Sleep 365" smartphone platform at the Sleep Disorders Diagnosis and Treatment Center of Hangzhou Seventh People's Hospital (China) between 1 November 2017 and 10 October 2024. Adults aged 18-65 years who met ICD-10 criteria for a depressive episode, had baseline PHQ-9 ≥10, and completed the PDQ-D-20 were included. PHQ-9 and PDQ-D-20 were assessed at baseline and at weeks 2, 4, 6 and 8. Correlations between depressive symptoms and subjective cognition were examined. Among 233 patients who completed all follow-ups, three hierarchical logistic regression models were built to predict antidepressant response (PHQ-9 reduction ≥50% at week 8), and their performance was evaluated using ROC curves, calibration, decision curve analysis and a nomogram. Results: In 321 patients with MDD, higher PHQ-9 scores were consistently associated with more severe PDQ-D-20 total and domain scores at all time points. Higher baseline PDQ-D-20 scores predicted smaller reductions in PHQ-9. Baseline depressive and cognitive measures did not show marked associations with age, sex, education level, occupation or illness duration. The fully adjusted logistic model that combined baseline PDQ-D-20, symptom scales and demographic/clinical variables showed good discrimination (AUC ≈0.91) and acceptable calibration, and baseline PDQ-D-20 remained an independent predictor of non-response. Conclusion: In this smartphone-based cohort of Chinese outpatients from a sleep-disorders clinic, subjective cognitive dysfunction was closely related to depressive symptom burden and predicted poorer antidepressant response, suggesting that routine cognitive assessment may help identify patients at risk of suboptimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.